TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04861519

Intervention type: OTHER
Intervention: Collecting invasive FFR measurements.
Description: Invasive FFR measurements from the patient's hospital records will be collected.
Study: NCT06364397

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERCP
Description: Participants will undergo ERCP and indomethacin will be administered rectally before procedure in participants with no known allergy to indomethacin. If the etiology of the participant is clearly defined during ERCP, the corresponding endoscopic treatment procedure will be performed. For others whose etiology are still unclear, pancreatic sphincterotomy and small caliber prophylactic pancreatic duct stent replacement will be performed. The participants will be observed closely after ERCP and record complications. Abdominal X-rays will be taken 2 weeks after ERCP to confirm spontaneous passage of the pancreatic duct stent, and the stent will be removed via gastroscopy if it still in place.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Health education and conservative management of clinical routines
Description: Participants will be given health education and conservative management of clinical routines. Clinical management is based on the pancreatic endocrine and exocrine function.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Health education and conservative management of clinical routines
Description: Participants will be given health education and conservative management of clinical routines. Clinical management is based on the pancreatic endocrine and exocrine function.
Study: NCT05657535

Intervention type: DEVICE
Group type: OTHER
Intervention: Low-intensity continuous ultrasound stimulator
Description: Stimulation 5 minutes, 3 times a day for 4 weeks on the knee
Study: NCT04984512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitizodone Phosphate tablets
Description: Mitizodone Phosphate tablets will be administered with food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitizodone Phosphate tablets
Description: Mitizodone Phosphate tablets will be administered with food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitizodone Phosphate tablets
Description: Mitizodone Phosphate tablets will be administered with food.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo-matching tablets
Description: Placebo will be administered with food.
Study: NCT05550896

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiogaphy
Description: Assessment of high velocity low amplitude signals on Doppler echocardiography

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiogaphy
Description: Assessment of high velocity low amplitude signals on Doppler echocardiography
Study: NCT06230835

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: Community Health Workers (CHWs) will undergo a 4-day training program on hypertension management, including screening, counseling, medication adherence, self-care, and referrals. They will then collaborate with healthcare facilities to conduct one-day hypertension screening camps. CHWs will form self-support groups for individuals with hypertension and hold monthly meetings to discuss control strategies, review BP logs, and promote healthcare visits, including family involvement. They will also maintain regular communication with healthcare facility in-charges to ensure effective collaboration in the 'Hypertension Care Cascade Model'. No any drugs will be used in the intervention group.
Study: NCT06030141

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sesame oil application
Description: sesame oil application

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nigella sativa oil application
Description: nigella sativa oil application
Study: NCT05682846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium glycerophosphate pentahydrate solution
Description: Glycophos is a 20 ml vial of Sodium glycerophosphate pentahydrate containing 1 mmol glycerophosphate and 2 mmol sodium per ml
Study: NCT04763018

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: iTEAR100
Description: Neurostimulation external nasal nerve to stimulate tear production

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iTEAR100
Description: Neurostimulation external nasal nerve to stimulate tear production
Study: NCT05829213

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: arch-bridge-type esophagogastric reconstruction after proximal gastrectomy
Description: 1. The lymphadenectomy is performed according to the Japanese Gastric Cancer Treatment Guidelines~2. Transection of the esophagus is performed using a linear stapler 2cm away from the proximal end of the tumor.~3. Creating the seromuscular flap (arch-bridge)~4. The remnant stomach is then inserted into the abdominal cavity, and pneumoperitoneum is re-established to perform the intracorporeal anastomosis.
Study: NCT05579483

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotics
Description: The prebiotics consists of three non-digestible carbohydrates (40% acacia gum, 20% partially hydrolyzed guar gum, and 40% resistant starch). During the 8-week intervention, two sachets (3 g per sachet) will be consumed per day, one in the morning and one in the evening.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotics
Description: The prebiotics consists of three non-digestible carbohydrates (40% acacia gum, 20% partially hydrolyzed guar gum, and 40% resistant starch). During the 8-week intervention, two sachets (3 g per sachet) will be consumed per day, one in the morning and one in the evening.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo consists of two digestible carbohydrates (20% maltodextrin and 80% corn starch). During the 8-week intervention, two sachets (3 g per sachet) will be consumed per day, one in the morning and one in the evening.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo consists of two digestible carbohydrates (20% maltodextrin and 80% corn starch). During the 8-week intervention, two sachets (3 g per sachet) will be consumed per day, one in the morning and one in the evening.
Study: NCT05322499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: 200mg/dose intravenous infusion, D1, once every 3 weeks (q3w);

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: 200mg/dose intravenous infusion, D1, once every 3 weeks (q3w);

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 100-125mg/m2，d1，d8；q21d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 135-175mg/m2，d1，Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel-albumin
Description: 100-135mg/m2, d1、d8，Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 60-75mg/m2，d1，Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: 12mg，qd，d1-d14，q3w
Study: NCT05042050

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A-iMAPS
Description: Imagery therapy targeting Psychosis-Related PTSD
Study: NCT05215717

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Administered Hypnosis
Description: Participants randomized to the self-administered hypnosis group will receive five audio-recordings of self-administered hypnosis, specifically targeting sleep improvement, which they will use for daily home practice.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Administered White Noise Hypnosis
Description: Participants randomized to the white noise hypnosis control will receive the same information and contact with the therapist, but will be provided with audio recordings that contain white noise as a sham hypnosis condition. These recordings include instructions and the use of white noise as a hypnotic induction.
Study: NCT06312189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valbenazine
Description: vesicular monoamine transporter 2 (VMAT2) inhibitor
Study: NCT05011253

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Trigger Microhematuria Alert
Description: To evaluate the effectiveness of an InBasket Results message in prompting providers to place appropriate follow up orders. The message will notify users that a patient has clinically significant microscopic hematuria and is at high risk for underlying malignancy and will include the official recommendations (imaging with a CT urogram, urology evaluation with cystoscopy).
Study: NCT04477460

Intervention type: DIETARY_SUPPLEMENT
Intervention: Thickened feeds
Description: Thickened feeds directed by medical team

Intervention type: DIETARY_SUPPLEMENT
Intervention: Non-thickened feeds
Description: Non-thickened feeds directed by medical team
Study: NCT06376370

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Application of computer-assisted cognitive rehabilitation program
Description: Since the program will respond to the patient's specific needs, the activity may become easier or more difficult depending on the patient's performance. Epilepsy patients will be encouraged by researchers during the exercises and will be able to give feedback on progress at the end of the session. After determining the appropriate time and day for each patient in the experimental group, the intervention will continue for 6 weeks with 45-minute sessions once a week.
Study: NCT05606978

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FASTb
Description: FAST blended

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FASTr
Description: FAST regular
Study: NCT05353868

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT05085483

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional Ketogenic Supplement
Description: This trial has 5 steps: (1) a 4-week run-in baseline; (2) a 4-week intervention phase to either active or placebo (3) a 4-week phase of washout; (4) the cross-over to the second 4-week active or placebo phase; (5) a 4-week follow-up.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Isocaloric placebo supplement
Description: Isocaloric placebo supplement
Study: NCT05229809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yiqi Wenyang Jiedu prescription
Description: The dosage form of the test drug is granule. Patients need to take 2 small packets in the morning and 2 small packets in the evening. The medicine needs to be melted in hot water before being taken. Every 4 weeks is a course of treatment, a total of 6 courses,The patients were followed up to 3 years after gastric cancer surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Simulation agent of Yiqi Wenyang Jiedu prescription
Description: It is prepared from maltodextrin and food coloring. The raw materials of maltodextrin conform to the relevant provisions of excipients - maltodextrin in the fourth part of Chinese Pharmacopoeia 2015 edition. Food coloring includes caramel coloring, egg yolk coloring and milk chocolate brown pigment, all of which are edible grade ingredients. Patients need to take 2 small packets in the morning and 2 small packets in the evening. The medicine needs to be melted in hot water before being taken. Every 4 weeks is a course of treatment, a total of 6 courses,The patients were followed up to 3 years after gastric cancer surgery.
Study: NCT04665700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 764198
Description: BI 764198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 764198
Description: BI 764198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 764198
Description: BI 764198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 764198
Description: BI 764198

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06304129

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood ponction
Description: Blood ponction
Study: NCT05251987

Intervention type: BIOLOGICAL
Intervention: PD1+ T Cell Expression
Description: The expression of PD1+ T cells was detected by flow cytometry in peripheral blood

Intervention type: BIOLOGICAL
Intervention: PD1+ T Cell Expression
Description: The expression of PD1+ T cells was detected by flow cytometry in peripheral blood
Study: NCT05604352

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DiaSole
Description: Diabetic ulcer offloading insole
Study: NCT04784377

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high intensity laser in addition to traditional physical therapy exercises
Description: high intensity laser will be used with 1064 nm wavelength and maximum of 25 W power. Analgesic and biostimulant modes were used in the present study.~Also the patients will receive traditional physical therapy exercises in the form of flexibility and strengthening exercises for shoulder muscles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low level laser in addition to traditional physical therapy exercises
Description: patients will receive low level Laser Therapy in addition to traditional physical therapy exercises.~diode laser device with a wavelength of 850nm, power output of 100mV, continuous wave and 0.07cm2 spot area laser will be used. The laser will be applied with a dosage of 5 joule/cm2 (totally 15-20 joule) at the most 5 painful points for 1 minute at each point over subacromial region of the shoulder.~Also the patients will receive traditional physical therapy exercises in the form of flexibility and strengthening exercises for shoulder muscles.

Intervention type: OTHER
Group type: OTHER
Intervention: traditional physical therapy exercises
Description: Also the patients will receive traditional physical therapy exercises in the form of flexibility and strengthening exercises for shoulder muscles.
Study: NCT06045351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Intervention Group Initial 12 weeks;~* VD supplementation (600,000 IU I/M) once during the study period~* Elemental calcium 1000 mg/day From 12-24 weeks: Standard PCOS;~* Glucophage XR 750 mg once at dinner for 15 days then twice daily~* Capsule Progeffik 100 mg once at night every 3 weeks, then 1 week off~* Calcium 1000 mg/day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: Active Comparator (Group B; n=71):~Initial-- 12 weeks;~* Standard PCOS;~* Glucophage XR 750 mg once at dinner for 15 days then twice daily~* Capsule Progeffik 100 mg once at night every 3 weeks, then 1 week off From 12- 24 weeks~* VD supplementation (600,000 IUI/M) once during the study period~* Calcium 1000 mg/day~* Standard PCOS Continued
Study: NCT05163717

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: INP105
Description: A single 5 mg dose of POD-OLZ (Precision Olfactory Delivery \[POD®\]-olanzapine)
Study: NCT05289791

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ultrasonic activation of bioceramic sealer
Description: activation of bioceramic sealer using ultrasonic tip for 20 seconds in buccolingual and mesiodistal direction

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ultrasonic activation of bioceramic sealer
Description: activation of bioceramic sealer using ultrasonic tip for 20 seconds in buccolingual and mesiodistal direction
Study: NCT05163717

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose of POD-placebo (Precision Olfactory Delivery \[POD®\]-placebo)
Study: NCT05730257

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot-Assisted Kidney Transplantation
Description: Robot-Assisted Kidney Transplantation takes place with the patient under general anaesthesia. Several ports are placed in the lower abdomen, for the entry of the camera, surgical instruments and manuel access. The DaVinci robot is placed between the patient's legs and docked to the ports. The iliac vascular bed is prepared and a peritoneal cavity created laterally. The kidney is introduced through the handport, regional hypothermia obtained via iceslush in the cavity and the vessel lumens flushed with heparin. The vessels are blocked during suturing with the kidney graft vessels anastomosed end-to-side to the external iliac vessels. The kidney graft is placed in the retroperitoneal cavity and a ureterovesical anastomosis performed ad modem Woodruff over double J stent. The ureter is placed extra peritoneally, fascia closed in layers and the skin using intracutaneous suturing. Perioperative prophylactics entail piperacillin/tazobactam and an indwelling bladder catheter is placed.
Study: NCT05373745

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Brains 1
Description: Active Brains 1 uses a multimodal approach to introduce and reinforce new skills, including didactics, in-session activities, discussions and weekly practice assignments (homework). The Active Brains sessions teach skills and strategies to manage early cognitive concerns and chronic pain. The format is an 8-week program with weekly meetings and a focus on relaxation response strategies, cognitive behavioral training, positive psychology and mind-body interactions. Active Brains 1 uses a wrist-worn digital monitoring device (ActiGraph) for recording of physical activity.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Active Brains 2
Description: This active comparison condition controls for the effect of time spent, group member support/feedback and interventionist support/feedback. Active Brains 2 addresses population-specific challenges of chronic pain and early cognitive decline symptoms. Participants also receive lifestyle education consistent from public health recommendations and standards for health promotion (e.g., Sleep, Nutrition, Healthy Weight and Medical appointments. The Active Brains 2 program consists on 8 group sessions (each session is 90 minutes) that occur concurrently with the active intervention condition. The Active Brains 2 is conducted in the same format as Active Brains 1, but participants are not taught the mind-body, walking or cognitive-behavioral skills. Active Brains 2 uses a wrist-worn digital monitoring device (ActiGraph) for recording of physical activity.
Study: NCT05184985

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TrueRelief device
Description: TrueRelief is an FDA-cleared treatment for chronic intractable pain, and as an adjunctive procedure in the management of post-surgical and post-traumatic acute pain. This 20,000 Hz high frequency electrical procedure is provided by clinicians trained in the use of the device and delivered via handheld steel-tipped probes to the source of pain and where pain is experienced.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TrueRelief device
Description: The placebo device looks and operates identically to the experimental TrueRelief device but will not emit any high frequency current.
Study: NCT05730257

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Kidney Transplantation
Description: Open Kidney Transplantation takes place with the patient under general anaesthesia. A jockey-stick (Gibson) incision is made in the left or right iliac fossa and the peritoneum is displaced. With the kidney under hypothermia, the iliac vascular bed is prepared, the vessel lumens flushed with heparin and a vascular clamp instrument is used to block the vessels during suturing. The kidney graft vessels are anastomosed end-to-side to the external iliac vessels and the ureterovesical anastomosis performed ad modem Woodruff over a double J stent. The kidney graft is placed in the cavity and the fascia is closed in layers and the skin using intracutaneous suturing. Perioperative prophylactics entail piperacillin/tazobactam and an indwelling bladder catheter is placed.
Study: NCT06100549

Intervention type: OTHER
Intervention: No intervention
Description: No intervention will be provided.

Intervention type: OTHER
Intervention: No intervention
Description: No intervention will be provided.
Study: NCT06391944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JMT101 Injection
Description: JMT101 Injection, 6 mg/kg intravenously, over 90 mins every 14 or 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib tablet
Description: Osimertinib 80 or 160mg po everyday
Study: NCT05657951

Intervention type: DEVICE
Intervention: ArcScan Insight 100 very high-frequency digital ultrasound
Description: The Insight-100 (ArcScan Inc., Golden, CO, USA) employs the high-frequency B-scan in the assessment of anterior segment parameters. Anormal saline coupling medium is formed with a disposable eyepiece between the 50 MHz transducer and the eye. The instrument moves the transducer in an arc so that the beam axis maintains approximate normality to the surface of the eye. The frequencies of cornea, anterior chamber, and lens are 60 MHz, 50 MHz and 50 MHz, respectively. The maximum arc scanning range is 70 degrees, and there is a linear scanning range of 29mm. The axial and lateral resolutions are 35 μm and 65 μm, respectively. It can measure structures behind the iris, including lens zonule.
Study: NCT05354830

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot Massage
Description: Foot Massage
Study: NCT05425693

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hybrid Warm-up
Description: Dynamic + stretching exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic Warm-up
Description: Dynamic exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching Warm-up
Description: Stretching exercises
Study: NCT04712799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Otrivin
Description: oxymetazoline nasal spray
Study: NCT06204302

Intervention type: DRUG
Intervention: Darolutamide (Nubeqa, BAY1841788)
Description: Retrospective cohort analysis, using Komodo Research Database (KRD)

Intervention type: DRUG
Intervention: Enzalutamide
Description: Retrospective cohort analysis, using Komodo Research Database (KRD)

Intervention type: DRUG
Intervention: Apalutamide
Description: Retrospective cohort analysis, using Komodo Research Database (KRD)